The Institute of Cancer Research, London and global healthcare company BTG have successfully concluded negotiations with a biopharmaceutical company, Carrick Therapeutics, to take a promising precision drug discovered at The Institute of Cancer Research into a later-stage clinical trial.

A new targeted treatment for ovarian cancer has shown ‘very promising’ results in an early clinical trial – shrinking tumours in half of women with the disease.